Topics

Zydelig (idelalisib; Gilead) Drug Overview & Product Profiles 2017-2026 – ResearchAndMarkets.com

08:04 EDT 12 Jul 2019 | Biotech 365

DUBLIN–(BUSINESS WIRE)–The “Zydelig” report has been added to ResearchAndMarkets.com’s offering. Zydelig (idelalisib; Gilead) is an oral, highly selective inhibitor of the phosphoinositide 3-kinase (PI3K) isoform p110-delta. In vitro studies have demonstrated that Zydelig results in decreased phosphorylation Akt and other … Continue reading

Original Article: Zydelig (idelalisib; Gilead) Drug Overview & Product Profiles 2017-2026 – ResearchAndMarkets.com

NEXT ARTICLE

More From BioPortfolio on "Zydelig (idelalisib; Gilead) Drug Overview & Product Profiles 2017-2026 – ResearchAndMarkets.com"

Quick Search